13
Articles Count
54586
Viewing Count
April 2022 saw a number of foreign and licensed drugs approved in China, with the majority of them in oncology and rheumatology.
Further information
China NMPA Approval Tracker
The month of March saw a string of approvals handed out by the NMPA, with the most significant being two domestically developed anti-PD-1 inhibitors getting green lighted to treat MSI-H/dMMR solid tumors in China for the first time ever.
Further information
China NMPA Approval Tracker
China could soon see a stream of foreign and homegrown JAK inhibitors being cleared or tested for atopic dermatitis, as competition among local players is heating up.
Further information
Feature
Chinese regulators approved 11 drugs in February. Uses and indications ran a wide gamut, including two drugs for atopic dermatitis and six new molecular entities that were approved for the first time.
Further information
China NMPA Approval Tracker
January 2022 saw 11 drugs get approval by Chinese drug regulators. JAK inhibitors started the year with momentum, with Eli Lilly's Olumiant, Pfizer's Xeljanz, and AbbVie's Rinvoq filing marketing applications for new indications.
Further information
China NMPA Approval Tracker
The NMPA’s run of speedy approvals continued in the last month of 2021 as Chinese regulators granted the first marketing approvals to 16 new drugs and accepted NDAs for 11 more new ones.
Further information
China NMPA Approval Tracker
Early-stage assets made up half of the licensing deals in 2021, up 10% from the previous year.
Further information
China Deals Tracker
Chinese regulators approved six new drugs in November, including the homegrown subcutaneous PD-L1 antibody KN035 (envafolimab) and third-generation BCR-ABL inhibitor HQP135 (olverembatinib).
Further information
China NMPA Approval Tracker
Chinese regulators approved three new molecular entities (NME) in October, including two innovative diabetes drugs.
Further information
China NMPA Approval Tracker
As companies worldwide pursue innovative drugs, one company is bucking the trend by developing low-cost me-too drugs. EQRx aims to develop affordable drugs with transparent pricing as it believes drug prices matter a lot in health care.
Further information
Feature
Personal Information
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.
Suggestions and feedback: Support@PharmaDJ.com
Record/License No.：沪ICP备17054709号-1